Showing 1,461 - 1,480 results of 4,380 for search 'significant ((((teer decrease) OR (((nn decrease) OR (greater decrease))))) OR (mean decrease))', query time: 0.43s Refine Results
  1. 1461
  2. 1462
  3. 1463
  4. 1464
  5. 1465
  6. 1466

    Table 1_Elevated mean arterial pressure and risk of impaired fasting glucose: a multicenter cohort study revealing age and sex interactions.docx by Yuye Lin (20084283)

    Published 2025
    “…Multivariate smooth splines analysis revealed a nonlinear relationship (P for nonlinearity < 0.05), with the curve slope decreasing as MAP exceeded 103.23 mmHg. Significant interaction effects between MAP and age or sex on IFG risk were also identified (P < 0.05).…”
  7. 1467
  8. 1468
  9. 1469
  10. 1470

    Data Sheet 1_Disproportionate impact of the COVID-19 pandemic on socially vulnerable communities: the case of Jane and Finch in Toronto, Ontario.docx by Zahra Movahedi Nia (9238798)

    Published 2025
    “…The number of patients during the COVID-19 pandemic versus before that decreased significantly more for pop-smear tests (p = 0.041) and surgery waitlists (p = 0.037) for the Jane and Finch community.…”
  11. 1471
  12. 1472

    Summary of study eligibility criteria. by Biban Gill (1473337)

    Published 2025
    “…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
  13. 1473

    Summary of study participation and feasibility. by Biban Gill (1473337)

    Published 2025
    “…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
  14. 1474

    Study variables. by Amit Timilsina (15203538)

    Published 2025
    “…The mean tree cover percentage also decreased from 21% in 2011 to 19% in 2016. …”
  15. 1475

    Descriptive statistics. by Amit Timilsina (15203538)

    Published 2025
    “…The mean tree cover percentage also decreased from 21% in 2011 to 19% in 2016. …”
  16. 1476
  17. 1477
  18. 1478
  19. 1479
  20. 1480